ID   Ma-Mel-54a
AC   CVCL_A189
SY   Ma-Mel_54a; Ma-Mel 54a
DR   cancercelllines; CVCL_A189
DR   Cosmic; 1846639
DR   Cosmic; 2163857
DR   Cosmic; 2686429
DR   ECACC; 13012484
DR   ESTDAB; ESTDAB-174
DR   GEO; GSM109072
DR   GEO; GSM2545603
DR   Progenetix; CVCL_A189
DR   Wikidata; Q54903814
RX   PubMed=16827748;
RX   PubMed=17311103;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=28561041;
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Gln959Pro (c.2876A>C); Zygosity=Homozygous (PubMed=28561041).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000007827; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ECACC=13012484; ESTDAB=ESTDAB-174
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12,13
ST   D16S539: 9,11
ST   D3S1358: 14,16
ST   D5S818: 12,13
ST   D7S820: 12 (ESTDAB=ESTDAB-174)
ST   D7S820: 12,13 (ECACC=13012484)
ST   FGA: 22,22.2
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C288 ! Ma-Mel-54b
SX   Female
AG   41Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-09-24; Version: 24
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=28561041; DOI=10.1038/ncomms15440; PMCID=PMC5460020;
RA   Sucker A., Zhao F., Pieper N., Heeke C., Maltaner R., Stadtler N.,
RA   Real B., Bielefeld N., Howe S., Weide B., Gutzmer R., Utikal J.S.,
RA   Loquai C., Gogas H., Klein-Hitpass L., Zeschnigk M., Westendorf A.M.,
RA   Trilling M., Horn S., Schilling B., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Acquired IFNgamma resistance impairs anti-tumor immunity and gives
RT   rise to T-cell-resistant melanoma lesions.";
RL   Nat. Commun. 8:15440.1-15440.15(2017).
//